Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial

Felix Espinoza, Miguel Tregnaghi, Angela Gentile, Katia Abarca, Javier Casellas, Alix Collard, Inge Lefevre, Jeanne-Marie Jacquet, Felix Espinoza, Miguel Tregnaghi, Angela Gentile, Katia Abarca, Javier Casellas, Alix Collard, Inge Lefevre, Jeanne-Marie Jacquet

Abstract

Background: Diphtheria-tetanus-whole-cell pertussis (DTPw)-based combination vaccines are an attractive option to rapidly achieve high coverage and protection against other important pathogens, such as hepatitis B virus (HBV) and Haemophilus influenzae type B (Hib). To ensure adequate antigen supply, GlaxoSmithKline Biologicals has introduced a new DTPw antigen source and developed a new DTPw-HBV/Hib combination vaccine containing a reduced amount of Hib polyribosylribitol phosphate (PRP). This study was undertaken to compare the immunogenicity and reactogenicity of this new DTPw-HBV/Hib vaccine with a licensed DTPw-HBV/Hib vaccine (Tritanrix™-HBV/Hib).

Methods: This was a randomized, partially-blind, multicenter study in three countries in Latin America (Argentina, Chile and Nicaragua). Healthy children received either the new DTPw-HBV/Hib vaccine (1 of 3 lots; n = 439; double-blind) or Tritanrix™-HBV/Hib (n = 146; single-blind) co-administered with oral poliovirus vaccine (OPV) at 2, 4 and 6 months, with a booster dose at 18-24 months.

Results: One month after the end of the 3-dose primary vaccination course, the new DTPw-HBV/Hib vaccine was non-inferior to Tritanrix™-HBV/Hib in terms of seroprotection/vaccine response rates for all component antigens; ≥97.3% and ≥93.9% of subjects in the two groups, respectively, had seroprotective levels of antibodies against diphtheria, tetanus, hepatitis B and Hib and a vaccine response to the pertussis component. Persistence of antibodies against all vaccine antigens was comparable between groups, with marked increases in all antibody concentrations after booster administration in both groups. Both vaccines were generally well-tolerated as primary and booster doses.

Conclusions: Results confirm the suitability of this new DTPw-HBV/Hib vaccine comprising antigens from a new source and a reduced PRP content for inclusion into routine childhood vaccination programs.

Trial registration: http://www.clinicaltrials.gov NCT00332566.

Figures

Figure 1
Figure 1
Subject disposition

References

    1. World Health Organization. Pertussis vaccines--WHO Position Paper. Wkly Epidemiol Rec. 2005;80(4):31–9.
    1. Dodd D. Benefits of combination vaccines: effective vaccination on a simplified schedule. Am J Manag Care. 2003;9(1 Suppl):S6–12.
    1. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt HJ, von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J. 2006;25(6):505–12.
    1. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496–500. doi: 10.1097/INF.0b013e31805d7f17.
    1. Cowgill KD, Ndiritu M, Nyiro J, Slack MP, Chiphatsi S, Ismail A, Kamau T, Mwangi I, English M, Newton CR, Feikin DR, Scott JA. Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA. 2006;296(6):671–8. doi: 10.1001/jama.296.6.671.
    1. Lee EH, Lewis RF, Makumbi I, Kekitiinwa A, Ediamu TD, Bazibu M, Braka F, Flannery B, Zuber PL, Feikin DR. Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study. Trop Med Int Health. 2008;13(4):495–502. doi: 10.1111/j.1365-3156.2008.02027.x.
    1. World Health Organization. Expanded programme on immunization: Global advisory group--Part I. Wkly Epidemiol Rec. 1992;67(3):11–5.
    1. World Health Organization. Global programme for vaccines and immunization. The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec. 1998;73(10):64–8.
    1. World Health Organization. WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec. 2006;81(47):445–52.
    1. Wenger J. Vaccines for the developing world: current status and future directions. Vaccine. 2001;19(13-14):1588–91. doi: 10.1016/S0264-410X(00)00356-X.
    1. Prymula R, Plisek S. Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines. Exp Opin Biol Ther. 2008;8(4):503–13. doi: 10.1517/14712598.8.4.503.
    1. Arístegui J, Usonis V, Coovadia H, Riedemann S, Win KM, Gatchalian S, Bock HL. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int J Infect Dis. 2003;7(2):143–51. doi: 10.1016/S1201-9712(03)90011-7.
    1. Gatchalian S, Reyes M, Bernal N, Lefevre I, David MP, Han HH, Bock HL, Wolter J, Schuerman L. A new DTPw-HBV vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin. 2005;1(5):198–203.
    1. Hla KH, Thein SA, Aye A, Han HH, Bock HL, David MP, Schuerman L. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content. Pediatr Infect Dis J. 2006;25(8):706–12. doi: 10.1097/01.inf.0000223488.80814.df.
    1. Tregnaghi M, López P, Rocha C, Rivera L, David MP, Rüttimann R, Schuerman L. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America. Rev Panam Salud Publica. 2006;19(3):179–88. doi: 10.1590/S1020-49892006000300006.
    1. Ortega-Barrìa E, Kanra G, Leroux G, Bravo L, Safary A, Lefevre I. DTPw-HBV/Hib 2.5 study group. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: Results from four phase III multicenter trials across three continents. Vaccine. 2007;25(50):8432–40. doi: 10.1016/j.vaccine.2007.09.045.
    1. Prymula R, David MP, Lefevre I, Kohl I, Stefkovicová M. The immunogenicity and reactogenicity of a new DTPw-HBV vaccine as a primary and booster vaccination course in healthy infants. Hum Vaccin. 2007;3(4):121–6.
    1. Gatchalian S, Reyes M, Bermal N, Chandrasekaran V, Han HH, Bock HL, Lefevre I. A new DTPw-HBV/Hib vaccine: Immune memory after primary vaccination and booster dosing in the second year of life. Human Vaccines. 2008;4(1):60–6.
    1. Linhares AC, Ruiz-Palacios GM, Guerrero ML, Salinas B, Perez-Schael I, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzábal JP, Damaso S, Tornieporth N, Sáez-Llorens X. et al.A short report on highlights of world-wide development of RIX4414: a Latin American experience. Vaccine. 2006;24(18):3784–5. doi: 10.1016/j.vaccine.2005.07.027.
    1. Santos JI, Martin A, De Leon T, Rivera L, Gaitán ME, Del Rio C, Oselka G, Cervantes Y, Rubio P, Clemens SA, de Mendonça JS. DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children. Vaccine. 2002;20(13-14):1887–93. doi: 10.1016/S0264-410X(01)00512-6.
    1. Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, Levine MM. Economisation of vaccination against Haemophilus influenzae type b: a randomized trial of immunogenicity of fractional-dose and two-dose regimens. Lancet. 1998;351(9114):1472–6. doi: 10.1016/S0140-6736(97)07456-4.
    1. Anderson EL, Frey S, Geldmacher K, Radley D, Lee A, Donnelly J, Mendelman PM, Dargan JM, Kaplan KM. Safety, tolerability and immunogenicity of low dose Haemophilus influenzae type b conjugated to the outer membrane protein complex of Neisseria meningitidis group b. Paediatr Infect Dis J. 2002;21(4):350–2. doi: 10.1097/00006454-200204000-00019.
    1. Campbell JD, Lagos R, Levine MM, Losonsky GA. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. Pediatr Infect Dis J. 2002;21(9):822–6. doi: 10.1097/00006454-200209000-00007.
    1. Nicol M, Huebner R, Mothupi R, Käyhty H, Mbelle N, Khomo E. Haemophilus influenzae type b conjugate vaccine diluted tenfold in diphtheria-tetanus-whole cell pertussis vaccine: a randomized trial. Paediatr Infect Dis J. 2002;2(2):138–41. doi: 10.1097/00006454-200202000-00010. 1.
    1. Huebner R, Nicol M, Mothupi R, Käyhty H, Mbelle N, Khomo E, Klugman KP. Dose response of CRM(197) and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines. Vaccine. 2004;23(6):802–6. doi: 10.1016/j.vaccine.2004.06.052.
    1. Tamm E, Veronese A, Contorni M, Meriste S, Nacci P, Viviani S. Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem™) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005;23(14):1715–9. doi: 10.1016/j.vaccine.2004.09.028.
    1. Halperin SA, Eastwood BJ, Barreto L, Friesen B, Medd L, Meekison W, Guasparini R. Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine. 1996;14(8):767–72. doi: 10.1016/0264-410X(95)00250-5.
    1. Pichichero ME, Deloria MA, Rennels MB, Anderson EL, Edwards KM, Decker MD, Englund JA, Steinhoff MC, Deforest A, Meade BD. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics. 1997;100(5):772–88. doi: 10.1542/peds.100.5.772.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner